Know Cancer

forgot password

A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer

Phase 2
18 Years
Open (Enrolling)
Metastatic Breast Cancer

Thank you

Trial Information

A Phase II Trial of Panitumumab, Gemcitabine, and Carboplatin in Triple-Negative Metastatic Breast Cancer

All patients will receive a pre-emptive skin care regimen during panitumumab therapy to
reduce skin toxicity. Treatment cycles will be repeated every 14 days (2 weeks). During each
treatment, panitumumab will be administered first, then carboplatin, then gemcitabine. All
drugs will be administered according to standard guidelines. Patients will be re-evaluated
for response after completion of 3 cycles (6 weeks) of treatment. Patients with objective
response or stable disease will continue treatment. Subsequent re-evaluations will occur
every 6 weeks. Patients will continue treatment with all three drugs until tumor
progression, or until unacceptable toxicity occurs. If patients experience toxicity caused
by gemcitabine/carboplatin and are continuing to benefit from treatment, panitumumab can be
continued as a single agent (at the same dose and schedule), at the discretion of the
investigator, until disease progression occurs.

Inclusion Criteria:

1. Female patients >=18 years of age.

2. Histologically or cytologically confirmed diagnosis of unresectable locally advanced
or stage IV breast cancer.

3. No more than 1 prior treatment regimen for metastatic breast cancer.

4. Estrogen receptor and progesterone receptor negative (defined as <10% staining by

5. Paraffin-embedded tumor tissue (from the primary tumor or metastasis) for biomarker
testing. (In the absence of paraffinembedded tissue, unstained paraffin-embedded
tumor slides are acceptable).

6. Measurable disease, as defined by the Response Evaluation Criteria in Solid Tumors
(RECIST version 1.1) guidelines

7. HER2 negative tumors. HER2 negativity must be confirmed by one of the following:

- FISH-negative (FISH ratio <2.2), or

- IHC 0-1+, or

- IHC 2-3+ AND FISH-negative (FISH ratio <2.2)

8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1.

9. Absolute neutrophil count (ANC) >=1.5 × 109/L; platelet count >=100 × 109/L;
hemoglobin >=9.0 g/dL.

10. Creatinine <=1.5 mg/dL, or creatinine clearance >=40 mL/min (as calculated by the
Cockcroft-Gault method, as follows: Female creatinine clearance = (140 - age) ×
(weight in kg) × 0.85 (serum creatinine × 72)

11. Adequate hepatic function, defined as follows: total bilirubin <=1.5 x ULN; aspartate
aminotransferase (AST) <=3 × ULN (or <= 5 x ULN if liver metastases); alanine
aminotransferase (ALT) <=3 x ULN (or <=5 x ULN if liver metastases).

12. Magnesium level >= the institutional lower limit of normal (LLN).

13. Women of childbearing potential must agree to use adequate contraception (per
institutional standard of care) during treatment and until 6 months after the last
administration of investigational products.

Exclusion Criteria:

1. Patients with brain metastases are not eligible.

2. History of another primary cancer, with the exception of the following:

- Curatively treated in situ cervical cancer;

- Curatively resected non-melanoma skin cancer;

- Other primary solid tumor curatively treated with no known active disease
present and no treatment administered for >=5 years prior to study enrollment.

3. History of interstitial lung disease (e.g., pneumonitis, pulmonary fibrosis), or any
evidence of interstitial lung disease on the CT scan of the chest performed at the
baseline visit.

4. Prior anti-EGFR antibody therapy (e.g., cetuximab), or treatment with small-molecule
EGFR inhibitors (e.g., gefitinib, erlotinib, lapatinib).

5. Radiotherapy <=14 days prior to study enrollment. Any acute effects of radiotherapy
must be resolved prior to the administration of study drugs.

6. Systemic chemotherapy, hormonal therapy, immunotherapy, or experimental or approved
proteins/antibodies (e.g., bevacizumab) <=21 days prior to study enrollment.

7. Prior therapy with gemcitabine or carboplatin in the metastatic setting is not
permitted. Patients who received gemcitabine or carboplatin as part of adjuvant
therapy are eligible, as long as recurrence was first documented >12 months after the
last exposure to the drug(s).

8. Major surgery within 28 days or minor surgery within 14 days of study enrollment.

9. Requirement of chronic use of immunosuppressive agents (e.g., methotrexate,

10. Any investigational agent or therapy <=30 days prior to study enrollment.

11. Uncontrolled or intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac

12. History of any medical or psychiatric condition or laboratory abnormality that, in
the opinion of the investigator, may increase the risks associated with the study
participation or administration of the investigational products, or that may
interfere with the interpretation of the results.

13. Unwillingness or inability to comply with study requirements.

14. Women who are pregnant or breastfeeding.

15. Patients with known human immunodeficiency virus (HIV), hepatitis C virus, and/or
acute or chronic hepatitis B virus infection.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the progression-free survival (PFS) of patients with triple-negative metastatic breast cancer when treated with panitumumab, gemcitabine, and carboplatin

Outcome Time Frame:

18 months

Safety Issue:


Principal Investigator

Denise A Yardley, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

February 2010

Completion Date:

December 2012

Related Keywords:

  • Metastatic Breast Cancer
  • Metastatic Breast Cancer
  • Triple Negative
  • Panitumumab
  • Vectibix
  • Gemcitabine
  • Gemzar
  • Carboplatin
  • Breast Neoplasms



Atlantic Health System Summit, New Jersey  07901
Florida Cancer Specialists Fort Myers, Florida  33901
Research Medical Center Kansas City, Missouri  64132
Family Cancer Center Collierville, Tennessee  38017
Peninsula Cancer Institute Newport News, Virginia  23601
Center for Cancer and Blood Disorders Bethesda, Maryland  20817
Tennessee Oncology Nashville, Tennessee  37203
Oncology Hematology Care Cincinnati, Ohio  45242
Providence Medical Group Terre Haute, Indiana  47802
Norton Cancer Institute Louisville, Kentucky  40207
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404
Nebraska Methodist Cancer Center Omaha, Nebraska  68114
Aventura Hospital and Medical Center Aventura, Florida  33180
Texas Health Physician Group Dallas, Texas  76011